The present study aims to test the effectiveness of β-glucan on reducing blood sugar levels in alloxaninduced mice
and potency to decrease cholesterol levels in the blood.β-Glucan, one of the primary cell wall components of Saccharomyces
cerevisiae. Several studies have reported the benefits of β- glucan as antiseptic, antioxidant, anti-aging, immune system
activators, protection against radiation, anti-inflammatory, anti-diabetic, anti-cholesterol, etc. This research was divided
into two, which were conducted separately. S. cerevisiae was cultured in yeast extract–peptone–glucose (YPG) broth
medium to produce beta-glucan. Cells were harvested at the stationary phase, washed, and disrupted using of sonication
method. The obtained cell walls were used to prepare alkali-soluble β-glucan (glucan-S1). In this regard, 2% sodium
hydroxide (NaOH) and 3% acetic acid were used in alkalineacid extraction. The number of rats used was 28 males with
body weight ranging from 160–200 grams. Administration of beta-glucan doses of 30.60 and 90 mg.kg-1 BW to
alloxan-induced mice can reduce blood glucose levels, by 66.90%, 62.95%, and 31.64%.
The potential use of beta-glucan extract as an anti-cholesterol agent was tested using
SpragueDawley strain rats. The experiments were divided into eight groups with four replicates:
GroupI (normal control), group II (fed with cholesterol without beta-glucan), group III (fed with
cholesterol + atorvastatin), group IV (fed with cholesterol + β-glucan standard), group V–VIII (fed of
cholesterol + β-glucan of S. cerevisiae with each dose of 10, 20, 30, and 40 mg.kg-1 BW. Rats were
fed with cholesterol for 14 days, except for group I. Analysis of blood was carried out to determine
total cholesterol, triglycerides, and malondialdehyde. The results showed that beta-glucan crude
obtained from S. cerevisiae cultures was 6.890 g. L-1. Beta-glucan extract of S. cerevisiae can reduce
total cholesterol approaching normal values at doses of 10 mg of 32.79% (blood plasma) and 33.71%
(in the liver). The extract was capable of reducing triglyceride levels in a dose of 10 mg of beta-glucan
64.43 % (blood plasma) and 30 mg of beta-glucan 19.45% (liver). Beta-glucan treatment at a 40 mg
dose can reduce MDA levels of 45.22% (blood plasma) and 42.64% (liver).
Author (s) Details
Kusmiati
Indonesian Culture Collection (InaCC), Research Center for Biology, Indonesian Institute of Sciences (LIPI), Jl Raya Jakarta Bogor Km 46, Cibinong Bogor 16911, Indonesia.
F. X. Rizky Dhewantara
Faculty of Pharmacy, University of Pancasila, Srengseng Sawah Jagakarsa, Jakarta, Indonesia.
Dendi Hermawan
Faculty of Pharmacy, Institute Science and Technology National-Jl. Moh. Kahfi II, JakSel, Indonesia.
View Book :- http://bp.bookpi.org/index.php/bpi/catalog/book/269
